<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159219</url>
  </required_header>
  <id_info>
    <org_study_id>CoVasc-ICH</org_study_id>
    <nct_id>NCT05159219</nct_id>
  </id_info>
  <brief_title>Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage</brief_title>
  <acronym>CoVasc-ICH</acronym>
  <official_title>A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous ICH and Established, or Risk Factors for, Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal is to establish the safety and efficacy of colchicine in ICH patients for&#xD;
      the prevention of major cardiovascular events and brain injury. Colchicine for the prevention&#xD;
      of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot&#xD;
      trial designed to obtain the factual feasibility prerequisites essential for the planning,&#xD;
      design, funding and execution of a subsequent phase III trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Feasibility, double-blind, placebo-controlled randomized controlled trial (RCT).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Over-encapsulated investigational product, with matching placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility - Recruitment</measure>
    <time_frame>From site activation until the end of recruitment (approximately 18 months)</time_frame>
    <description>Recruitment Rate, mean of approximately 10 participants per site, per year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility - Refusal Rate</measure>
    <time_frame>Exploratory, from first patient, first visit, until the common study end date (approximately 30 months)</time_frame>
    <description>Refusal to participate is not a substantial barrier to recruitment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility - Retention Rate</measure>
    <time_frame>At 6 months from randomization</time_frame>
    <description>Retention of ≥90% of study participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility - Medication Adherence</measure>
    <time_frame>At 12 months from randomization</time_frame>
    <description>Adherence &gt;75%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Intracranial Hemorrhages</condition>
  <arm_group>
    <arm_group_label>Oral Colchicine, 0.5mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active colchicine tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral matching placebo, once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Pill</intervention_name>
    <description>Anti-inflammatory</description>
    <arm_group_label>Oral Colchicine, 0.5mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inert ingredients</description>
    <arm_group_label>Oral matching placebo, once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Adult participants are eligible to be included in the study only if all of the following&#xD;
        criteria apply:&#xD;
&#xD;
        Type of Participant and Disease Characteristics&#xD;
&#xD;
          1. Participants with documented spontaneous intraparenchymal hemorrhage within 48 hours&#xD;
             of symptom onset (or last seen normal) and&#xD;
&#xD;
          2. Qualifying for at least one of the following categories:&#xD;
&#xD;
             i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe&#xD;
             atherosclerotic vascular disease), or ii. visualized extracranial&#xD;
             cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion&#xD;
             or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate&#xD;
             atherosclerotic vascular disease), or iii. two or more risk factors including: age 60&#xD;
             years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease&#xD;
             (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild&#xD;
             atherosclerotic vascular disease)&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          3. Capable of giving signed informed consent either independently, or by a legally&#xD;
             authorized representative (LAR), which includes compliance with the requirements and&#xD;
             restrictions listed in the informed consent form (ICF) and in this protocol.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Secondary causes of ICH (relating to trauma, macrovascular anomalies, neoplasms or&#xD;
             bleeding diathesis)&#xD;
&#xD;
          2. Inflammatory bowel disease or chronic diarrhea&#xD;
&#xD;
          3. Cirrhosis or severe hepatic dysfunction&#xD;
&#xD;
          4. Renal insufficiency (eGFR &lt;15mL/min)&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
          5. Concurrent treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin,&#xD;
             darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir,&#xD;
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or&#xD;
             P-gp inhibitors (cyclosporine, ranolazine)&#xD;
&#xD;
          6. Known allergy or sensitivity to colchicine&#xD;
&#xD;
          7. Strong indication for colchicine where assignment to placebo is deemed unacceptable&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
          8. Pregnant or breast-feeding&#xD;
&#xD;
          9. Inability to adhere to study procedures&#xD;
&#xD;
         10. Estimated life expectancy less than 6 months at the time of enrollment&#xD;
&#xD;
         11. Close affiliation with the investigational site; e.g. a close relative of the&#xD;
             investigator, dependent person (e.g., employee or student of the investigational site)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aristeidis Katsanos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashkan Shoamanesh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin W Reeh, MSc</last_name>
    <phone>905-521-2100</phone>
    <email>CoVasc-ICH@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Taylor, BSc</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>40508</phone_ext>
    <email>CoVasc-ICH@phri.ca</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracranial Hemorrhage</keyword>
  <keyword>Colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

